Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 1.5300
- +0.0200+1.32%
Close Feb 14 16:00 ET
- 1.5000
- -0.0300-1.96%
Post 19:13 ET
9.33MMarket Cap-0.59P/E (TTM)
1.5500High1.4533Low40.64KVolume1.5200Open1.5100Pre Close61.54KTurnover0.75%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High3.76P/B8.29MFloat Cap1.290052wk Low--Dividend TTM5.42MShs Float1419.0000Historical High--Div YieldTTM6.40%Amplitude1.2900Historical Low1.5140Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Can-Fite BioPharma Stock Forum
When and where will Can-Fite BioPharma (CANF) present at the BIO CEO Conference 2025?
Can-Fite BioPharma will present on February 10, 2025, at 3:45 pm EST at the New York Marriott Marquis in New York City.
What clinical trials is CANF currently conducting with Namodenoson?
Namodenoson is currently in a pivotal Phase III trial for advanced liver cancer and a Phas...
heading up from here
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
Can-Fite Secures US Patent for Novel Obesity Drug Namodenoson Through 2042
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
Can-Fite BioPharma (NYSE American: CANF) announced that its lead drug candidate Namodenoson has been granted a US patent for use as an anti-obesity drug. The patent (No. 17/309,952), expiring in 2042, covers methods of treating obese patients with oral Namodenoson.
The drug demonstrated effectiveness by reducing fat levels through increased adiponectin hormone production and showed...
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
Zach rating of Strong Buy puts it in their top 5%
No comment yet